191 related articles for article (PubMed ID: 31168393)
1. High incidence of atrial fibrillation in patients treated with ibrutinib.
Baptiste F; Cautela J; Ancedy Y; Resseguier N; Aurran T; Farnault L; Escudier M; Ammar C; Gaubert M; Dolladille C; Barraud J; Peyrol M; Cohen A; Paganelli F; Alexandre J; Ederhy S; Thuny F
Open Heart; 2019; 6(1):e001049. PubMed ID: 31168393
[TBL] [Abstract][Full Text] [Related]
2. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
Singh A; El Hangouche N; McGee K; Gong FF; Lentz R; Feinglass J; Akhter N
Echocardiography; 2021 Jan; 38(1):81-88. PubMed ID: 33594858
[TBL] [Abstract][Full Text] [Related]
3. Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.
Mattiello V; Barone A; Giannarelli D; Noto A; Cecchi N; Rampi N; Cassin R; Reda G
Hematol Oncol; 2023 Aug; 41(3):363-370. PubMed ID: 36762406
[TBL] [Abstract][Full Text] [Related]
4. The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation.
Patel R; Singh A; Meng Z; Baldridge AS; Addison D; Akhter N
Leuk Lymphoma; 2024 Feb; 65(2):168-174. PubMed ID: 37953609
[TBL] [Abstract][Full Text] [Related]
5. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.
Diamond A; Bensken WP; Vu L; Dong W; Koroukian SM; Caimi P
JACC CardioOncol; 2023 Apr; 5(2):233-243. PubMed ID: 37144107
[TBL] [Abstract][Full Text] [Related]
7. Determinants and prognostic significance of immediate atrial fibrillation recurrence following cardioversion in patients undergoing pulmonary vein isolation.
Husser D; Bollmann A; Kang S; Stridh M; Sornmo L; Olsson SB; Bhandari AK; Cannom DS
Pacing Clin Electrophysiol; 2005 Feb; 28(2):119-25. PubMed ID: 15679641
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-related atrial fibrillation: A single center Australian experience.
Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib-Associated Atrial Fibrillation.
Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
[TBL] [Abstract][Full Text] [Related]
11. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE; Levine LB; Brumbaugh J; Coggins J; Zhao Q; Ruppert AS; Rogers K; McCoy A; Mousa L; Guha A; Heerema NA; Maddocks K; Christian B; Andritsos LA; Jaglowski S; Devine S; Baiocchi R; Woyach J; Jones J; Grever M; Blum KA; Byrd JC; Awan FT
Blood Adv; 2017 Sep; 1(20):1739-1748. PubMed ID: 29296820
[TBL] [Abstract][Full Text] [Related]
12. Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
Andersson ML; Johansson H; Österborg A; Månsson-Broberg A; Hansson L; Palma M
Eur J Haematol; 2023 Nov; 111(5):748-756. PubMed ID: 37565648
[TBL] [Abstract][Full Text] [Related]
13. Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.
Rasmussen KM; Patil V; Burningham Z; Yong C; Sauer BC; Halwani AS
Fed Pract; 2020 May; 37(Suppl 2):S44-S49. PubMed ID: 32952387
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
15. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
[TBL] [Abstract][Full Text] [Related]
16. Trigger-based mechanism of the persistence of atrial fibrillation and its impact on the efficacy of catheter ablation.
Inoue K; Kurotobi T; Kimura R; Toyoshima Y; Itoh N; Masuda M; Higuchi Y; Date M; Koyama Y; Okamura A; Iwakura K; Fujii K
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):295-301. PubMed ID: 22042883
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
[TBL] [Abstract][Full Text] [Related]
18. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
